Eligible patients were randomly assigned at enrollment to receive three weekly doses of epoetin alfa 40,000 U subcutaneously ( SC ) , followed by either standard weekly epoetin alfa ( 40K arm ) or 120,000 U of epoetin alfa ( 120K arm ) SC every 3 weeks for 18 additional weeks .
not found